E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Thrombocytopenia in subjects with ITP |
Trombocitopenia in pazienti affetti da ITP |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021245 |
E.1.2 | Term | Idiopathic thrombocytopenic purpura |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the safety of AMG 531 as a long-term treatment in thrombocytopenic subjects with ITP. |
Determinare la sicurezza e la tollerabilita' di AMG 531 come trattamento a lungo termine in pazienti trombocitopenici affetti da ITP. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the long-term platelet response to AMG 531 To evaluate possible reductions in the dose of concurrent ITP therapies while receiving AMG 531 To evaluate changes in Patient Reported Outcomes (PRO) due to the use of AMG 531 |
Valutare la risposta della conta piastrinica nel trattamento a lungo termine con AMG 531
Valutare le possibili riduzioni di dose delle altre terapie concomitanti per la ITP mentre il soggetto riceve AMG 531.
Valutare i cambiamenti dei questionari sulla qualita' di vita 'Patient Reported Outcomes' (PROs) dovuti all'uso di AMG 531. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subject previously completed an AMG 531 ITP study Before any study-specific procedure, the appropriate written informed consent (and assent, if applicable) was obtained |
Soggetti che hanno precedentemente completato uno studio con AMG 531 sulla ITP.
Consenso informato scritto prima di qualsiasi precedura studio- specifica |
|
E.4 | Principal exclusion criteria |
Subject has any bone marrow stem cell disorders or new active malignancies diagnosed since enrollment in the previous AMG 531 ITP study Subject received any alkylating agents within 4 weeks before the Screening visit or anticipated use during the time of the proposed study Subject is currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous AMG 531 ITP study), or subject is receiving other investigational agent(s) other than AMG 531. Subject of childbearing potential is evidently pregnant (eg, positive β-hCG test) or is breast feeding Subject is not using adequate contraceptive precautions Subject will not be available for follow-up assessments Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and does not have a legally-acceptable representative and/or is unable to comply with study procedures |
Pazienti che abbiano una qualsiasi patologia delle cellule staminali del midollo osseo o una nuova diagnosi di tumore attivo rispetto all'arruolamento nello studio precedente con AMG 531.
Pazienti che abbiano ricevuto qualsiasi agente alchilante nelle 4 settimane che precedono la visita di screening o di cui si e' a conoscenza che dovranno riceverne durante il corso dello studio.
Pazienti attualmente arruolati in un altro studio clinico che hanno ricevuto qualsiasi farmaco sperimentale o dispositivi medici non ancora approvati dalle autorita' regolatorie nelle ultime 4 settimane che precedono lo screening (ad eccezione di AMG 531)
Gravidanza o allattamento.
Pazienti in eta' fertile che rifiutano di ricorrere a idonei metodi di controllo delle nascite.
Pazienti che non si rendano disponibili per le valutazioni di follow-up.
Pazienti che, a giudizio del medico, non intendano o non siano in grado di conformarsi alle procedure previste dallo studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence of adverse events, including clinically significant changes in laboratory values and incidence of antibody formation |
Incidenza degli eventi avversi, compresi i cambiamenti significativi nei valori di laboratorio e l'incidenza della formazione di anticorpi. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 46 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Lo studio durera' fino a progressione di malattia, tossicita' inaccettabile, rinuncia o decesso da parte del paziente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |